Abbott & Novo Nordisk India Join Forces to Launch New Semaglutide Brand “Extensior” and Expand Diabetes Care Access

 

Diabetes care in India is set for a major expansion as Abbott and Novo Nordisk India have announced a strategic partnership to introduce a second brand of the GLP‑1 diabetes treatment semaglutide  marketed globally as Ozempic  under the name Extensior.

Extensior semaglutide injection pen for type 2 diabetes treatment in India
Abbott and Novo Nordisk India collaborate to launch Extensior, a second semaglutide brand to expand diabetes care access across India.


Under this collaboration, Abbott will leverage its extensive distribution network across India to commercialise Extensior and reach a broader range of patients beyond the urban centres where Novo Nordisk has traditionally focused.

What Is Extensior and Why It Matters

Extensior is a once‑weekly semaglutide injection approved as an adjunct to diet and exercise to manage blood glucose levels in adults living with type 2 diabetes. Semaglutide  a GLP‑1 receptor agonist  has shown significant benefits in lowering HbA1c, aiding weight control, and reducing risks of heart and kidney complications among people with type 2 diabetes.

While Ozempic is already available in India, the launch of Extensior will help improve access  particularly in regions where availability has been limited  by combining Novo Nordisk’s clinical expertise with Abbott’s supply and reach.

What This Means for Patients

India carries one of the largest diabetes burdens in the world with over 100 million people affected, and that number is expected to rise sharply in the coming decades. Extensior’s expanded distribution may make cutting‑edge diabetes care more accessible, especially for patients outside major cities who struggle to find advanced therapies.

Both companies have highlighted that this partnership reflects a shared commitment to tackling the diabetes epidemic in India. Extensior will be offered in a convenient weekly injection device with a range of dose strengths, and is expected to be available soon.

Comments

Popular posts from this blog

Shyam Maheshwari SSG Shares Insights on SVB’s Collapse and the Future of Startup Banking

Shyam Maheshwari SSG: The Journey of a Global Investor from Bihar to Singapore’s Financial Hub

Gunman kills 4 before shooting himself at hospital in US